iBio Doses First Patient in Phase 1 Trial for Obesity Drug IBIO-600, Now a Clinical-Stage Company
IBIO has more than doubled off its 52-week low of $0.556.
Summary
iBio has dosed the first participant in its Phase 1 clinical trial for IBIO-600, an anti-myostatin monoclonal antibody targeting obesity. This significant milestone officially transitions iBio into a clinical-stage biotechnology company. The news follows regulatory clearance received in Australia on April 8th and comes after the company recently resolved its going concern issues and extended its cash runway to Q4 2028. IBIO-600 aims to preserve muscle and improve body composition, potentially addressing a key challenge in the growing obesity treatment market. The Phase 1 study, enrolling approximately 32 individuals, is expected to complete in the second half of 2027.
At the time of this announcement, IBIO was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.9M. The 52-week trading range was $0.56 to $3.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.